[Insulin therapy using a new injection device. Experience with 36 type I diabetics].
Thirty-six type I diabetics were switched from conventional insulin therapy to the basic bolus principle (combination of an ultralong-acting human insulin with preprandial old insulin administration) with a new injection device (NovoPen). In the observation period of four months, a better metabolic situation could be attained (HbA1c before switching 9.4%, after switching 8.41%; P less than 0.01) with approximately the same daily amount of injected insulin (before treatment 42.7 +/- 9.3 IU, after treatment 43.5 +/- 7.1 IU) in another distribution and with the injection device. All patients gave a positive appraisal of the handling and technique with the NovoPen. The new treatment principle is to be applied especially in patients with inadequate blood sugar values under conventional therapy as well as in diabetic secondary complications which require optimal compensation. Furthermore, this principle of treatment is also suitable for prevention of secondary lesions owing to diabetes. Under the precondition of more intensive attention of the patient to his metabolic disorder (self-checking of blood sugar, diabetes training), the basic bolus principle provides more freedom in daily routine and thus greater quality of life.